<DOC>
	<DOCNO>NCT02638038</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group study compare two dos INT131 ( 3 mg 1 mg ) administer orally ( PO ) daily ( QD ) versus placebo 1 tablet PO QD subject treatment-naïve RRMS ≤ 3 year .</brief_summary>
	<brief_title>This Randomized Study Comparing Two Doses INT131 ( 3 mg 1 mg ) Administered Orally ( PO ) Daily ( QD ) Versus Placebo 1 Tablet PO QD Subjects With Treatment-naïve RRMS ≤ 3 Years</brief_title>
	<detailed_description>This randomize , double-blind , parallel group study compare two dos INT131 ( 3 mg 1 mg ) administer orally ( PO ) daily ( QD ) versus placebo 1 tablet PO QD subject treatment-naïve RRMS ≤ 3 years.. Part 2 study open-label , Subjects complete 6 month evaluation study drug Part 1 without serious study drug-related treatment emergent adverse event ( TEAE ) switch INT131 1 mg PO QD follow additional 6 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Signed informed consent study procedures 2 . Male female subject age 1850 3 . Subjects diagnosis RRMS three ( 3 ) year less base date diagnosis 4 . At least one gadoliniumpositive lesion within twelve month enrollment study document subject 's clinical chart 1 . Subjects history presence chronic disease immune system RRMS 2 . Subjects diagnosis primary secondary progressive multiple sclerosis 3 . Ten ( 10 ) active gadolinium CE MRIdetected lesion baseline MRI obtain visit 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>